Bolt Biotherapeutics, Inc. Share Price & Technical Analysis
BOLT · $4.59 (-0.65%)
Healthcare / Biotechnology
$4.59
-0.65%
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agoni…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-6% return in May, -12% avg return in past 3 year May month.
-19% return in 2026, -39% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -24% | -11% | 14% | -6% | – | – | – | – | – | – | – | -19% |
| 25 | -12% | -5% | -15% | -13% | -12% | -6% | 0% | -7% | 2% | 9% | -11% | 8% | -63% |
| 24 | -11% | 14% | 23% | -22% | -33% | -1% | 2% | -8% | -4% | -2% | -2% | -15% | -58% |
| 23 | 11% | 10% | -13% | 16% | 9% | -26% | 4% | -19% | -5% | -4% | -11% | 33% | 4% |
| 22 | -21% | -9% | -23% | -43% | 8% | 18% | 8% | -20% | -21% | -7% | 4% | -10% | -117% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$8.88M
P/E ratio
—
52W high
$7.35
52W low
$3.91
Volume
33,166
Beta
1.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Bolt Biotherapeutics, Inc. share price today?
- Bolt Biotherapeutics, Inc. (BOLT) last traded around $4.59 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BOLT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BOLT. Download the app for real-time alerts.
- How can I analyze Bolt Biotherapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.